InVivoScribe

Executive Summary

InVivoScribe is a private, San Diego-based leader in precision molecular diagnostics for hematologic cancers, with a focus on minimal residual disease (MRD) monitoring and companion diagnostics (CDx). The company develops and commercializes standardized IVD assays, reagents, and software, and operates LabPMM, a global clinical testing service. Founded in 1999, InVivoScribe has established a strong reputation in the leukemia and lymphoma diagnostics space, offering products that enable standardized MRD detection and CDx for targeted therapies. The company's platform is validated across multiple labs and is used in clinical trials and routine patient monitoring. With increasing adoption of MRD as a surrogate endpoint in hematologic cancers and growing demand for CDx in precision oncology, InVivoScribe is well-positioned for growth. The company's ability to combine IVD manufacturing with clinical testing services provides a unique competitive advantage. However, as a private entity, financial details are limited. The diagnostics market remains competitive, with pressure from liquid biopsy and next-gen sequencing approaches. InVivoScribe's steady market presence and regulatory experience suggest a stable outlook, with potential upside from new product launches or strategic partnerships.

Upcoming Catalysts (preview)

• Q3 2026FDA approval or clearance for expanded MRD assay use (e.g., in solid tumors or new indications)55% success
• Q4 2026New companion diagnostic partnership with a major pharmaceutical company for a targeted therapy40% success
• H1 2027Launch of a next-generation sequencing (NGS)-based MRD panel to compete with emerging liquid biopsy technologies30% success